STUDY ON DAPTOMYCIN USE AS A FIRST STEP TOWARDS AN ANTIMICROBIAL STEWARDSHIP PROGRAMME

García-Sánchez S1,2, García-Moreno FJ1,2, Rodríguez-González C1,2, Chamorro-De Vega E1,2, García-Martín E1,2, Valerio-Minerio M2,3, Muñoz P2,3, Bouza E2,3, Herranz-Alonso A1,2, Sanjurjo-Sáez M1,2
1Servicio de Farmacia. Hospital General Universitario Gregorio Marañón.
2Instituto de Investigación Sanitaria Gregorio Marañón (IISGM). Madrid, España
3Servicio de Microbiología y Enfermedades Infecciosas. Hospital General Universitario Gregorio Marañón.

OBJECTIVE

Background: The use of daptomycin has increased in Spain since its approval and there is a great variability in the dosage and in the criteria for its use in clinical practice.

OBJECTIVE: To report the real use of daptomycin in clinical practice including its efficacy and tolerability as a first measure for the establishment of improvement actions.

METHODS

Inclusion time
01/01/2017 – 31/12/2017

Eligible criteria
Patients who started treatment with daptomycin

Follow up
Until hospital discharge

RESULTS

Daptomycin dose
≤ 6 mg/kg/day
6-10 mg/kg/day
≥ 10 mg/kg/day

176 treated patients
(61.9% men, median age 70 years – IQR: 57-79)

Infection type
Bacteraemia
64.2 %
35.8 %

Clinical outcomes
Effectiveness
Satisfactory clinical evolution in 77.7% of patients.
Total mortality = 17.6%
Mortality related to the infection = 7.4%
Safety
Discontinuations due to adverse events = 5 patients: increased CPK (1), urticaria (2), cholestasis (1), rhabdomyolysis (1).

Microbiological isolates
Staphylococcus aureus
35
Staphylococcus coagulase negative
12
Enterococcus fecalis
20

- Daptomycin is a well-tolerated and effective drug but is often prescribed empirically or in infections not caused by S. aureus methicillin resistant.
- The follow-up of patients treated with daptomycin should be considered a priority intervention within the Antimicrobial Stewardship Programmes.

CONCLUSIONS

sgarciasanchez2@salud.madrid.org www.madrid.org/hospitalgregoriomaron/farmacia @farma_gregorio

Abstract Number: 4CPS-053
ATC Code: J01 - Antibacterials for systemic use